

Document allergies on approved form and ensure medication reconciliation has been reviewed as per organizational process

## CHFS Heart Failure Order Set

### Admission

Admit to: \_\_\_\_\_ Dr. \_\_\_\_\_ to assume MRP

Diagnosis: Heart Failure

Date of Admission: \_\_\_\_\_ (yyyy-mm-dd)       Expected Date of Discharge: \_\_\_\_\_ (yyyy-mm-dd)

Allergies or hypersensitivities?  None Known       Yes: Refer to organization's allergy documentation/process

Code Status:     Full Resuscitation       DNR       \_\_\_\_\_

Primary Care Provider: \_\_\_\_\_

Inform Primary Care Provider of patient's hospitalization for HF

### Precautions

Antibiotic Resistant Organism (ARO) Screening and Management Clinical Protocol

\_\_\_\_\_

### Consults

**Note:** If patient at nutritional risk based on the Malnutrition Screening Tool assessment, ensure dietitian consulted.

Cardiologist - Reason: \_\_\_\_\_       Pharmacist - Reason: \_\_\_\_\_

Dietitian - Reason: \_\_\_\_\_       PT for early ambulation

Internist - Reason: \_\_\_\_\_       RRT - Reason: \_\_\_\_\_

OT to screen for frailty       SW for discharge planning

Palliative Care Service - Reason: \_\_\_\_\_       \_\_\_\_\_ - Reason: \_\_\_\_\_

### Diet/Nutrition

NPO, medications with sips       NPO, no PO medications

Cardiac<sup>1</sup>     Diabetic \_\_\_\_\_ kJ       Renal       \_\_\_\_\_

**Restrictions:**  \_\_\_\_\_ Litres fluid in 24 hours (1.5 or 2 Litres<sup>1</sup>)       2 g Na in 24 hours<sup>1</sup>     \_\_\_\_\_

\_\_\_\_\_

### Activity

Activity as tolerated, encourage early mobilization<sup>2</sup>     Early ambulation, aim to ambulate three times per day

\_\_\_\_\_

### Vitals/Monitoring

#### Vitals

Weigh patient on admission: Weight: \_\_\_\_\_ kg

Weigh daily in morning<sup>1</sup> after voiding, before breakfast

Vitals, SpO<sub>2</sub>, Pain Score as per policy/procedure

Submitted by: \_\_\_\_\_  Read Back

ID      PRINTED NAME      YYYY-MM-DD HH:MM

Practitioner: \_\_\_\_\_

ID      PRINTED NAME      YYYY-MM-DD HH:MM      SIGNATURE

Document allergies on approved form and ensure medication reconciliation has been reviewed as per organizational process

## CHFS Heart Failure Order Set

### Vitals/Monitoring Continued...

#### Monitoring

- Telemetry for 48 hours, then reassess
- CAM score q \_\_\_\_\_ h and PRN
- Intake and Output q \_\_\_\_\_ h
- Assess falls risk and implement falls prevention strategies as per policy/procedure

#### Capillary Blood Glucose Monitoring

- For patient with diabetes, Capillary Blood Glucose monitoring as per applicable diabetes management order set
- Capillary Blood Glucose \_\_\_\_\_ (frequency)

### Respiratory

#### Oxygen Therapy

\*\*\*Supplemental oxygen is recommended in patients who are hypoxemic to achieve an oxygen saturation greater than 90%\*\*\*<sup>1,3</sup>

- Target SpO<sub>2</sub>:  88 - 92%<sup>4,5</sup>  Greater than 92%<sup>5,6</sup>  SpO<sub>2</sub>: \_\_\_\_\_ - \_\_\_\_\_ %
- Oxygen Titration Clinical Protocol

#### Patient with Obstructive or Central Sleep Apnea

- Patient to use own PAP machine at patient's prescribed settings<sup>4,7</sup> after RRT/BioMed equipment check
- Request RRT to assess PAP machine, prescribed settings, and to enable O<sub>2</sub> entrainment if O<sub>2</sub> required
- \_\_\_\_\_

### Lab Investigations

#### Lab Investigations on Admission (if not already done in ED)

##### Hematology, Coagulation

- CBC<sup>1,3</sup>  APTT  INR  \_\_\_\_\_
- Ferritin<sup>3</sup>  Transferrin saturation<sup>3</sup>  Serum iron<sup>3</sup>

##### Chemistry

**Note:** Digoxin level may be considered if not performed in the past 6 months. If digoxin level ordered, ensure level is not in toxic range.

- Electrolytes<sup>1,3</sup>  Lactate  BNP<sup>1,3</sup>  A1C<sup>1,3</sup>
- Creatinine<sup>1,3</sup>  Ca<sup>1,3</sup>  NT-proBNP<sup>1,3</sup>  TSH<sup>1,3</sup>
- Glucose<sup>1,3</sup>  Mg<sup>1,3</sup>  Troponin<sup>3</sup>  Digoxin level
- Albumin  ALT, ALP, Bilirubin<sup>3</sup>  Uric Acid  \_\_\_\_\_
- HDL, LDL, Total Cholesterol, Triglycerides<sup>3</sup>  LDH  \_\_\_\_\_

#### Lab Investigations Day 2 and Onwards

\*\*\*Consider daily electrolytes, creatinine while patient is receiving IV diuretic therapy\*\*\*<sup>8</sup>

- Daily Electrolytes, Creatinine

Submitted by: \_\_\_\_\_  Read Back

ID \_\_\_\_\_ PRINTED NAME \_\_\_\_\_ YYYY-MM-DD HH:MM \_\_\_\_\_

Practitioner: \_\_\_\_\_

ID \_\_\_\_\_ PRINTED NAME \_\_\_\_\_ YYYY-MM-DD HH:MM \_\_\_\_\_ SIGNATURE \_\_\_\_\_

Document allergies on approved form and ensure medication reconciliation has been reviewed as per organizational process

## CHFS Heart Failure Order Set

### Diagnostics

- 12-Lead ECG<sup>1,3</sup>  15-Lead ECG
- CXR PA + Lateral<sup>1,3</sup> Reason: \_\_\_\_\_
- \*\*\*Repeat echocardiogram **only** if no recent assessment of LV function performed in past 12 months and clinical status change warrants investigation\*\*\*
- Echocardiogram<sup>1-3</sup> Reason: \_\_\_\_\_
- \_\_\_\_\_ Reason: \_\_\_\_\_

### IV Therapy

- Saline lock; flush as per policy/procedure  \_\_\_\_\_ at \_\_\_\_\_ mL/h

### Heart Failure Medications

#### Diuretics

\*\*\*IV diuretics are recommended as first-line therapy for patients with pulmonary or peripheral congestion\*\*\*<sup>1</sup>  
 \*\*\*If symptomatic hypotension arises, consider holding diuretics and reassessing for volume overload\*\*\*  
 \*\*\*Assess daily volume status and manage diuretics accordingly\*\*\*

- furosemide \_\_\_\_\_ mg IV for 1 dose STAT (**max 200 mg/dose**)
- furosemide \_\_\_\_\_ mg IV q \_\_\_\_\_ h
- furosemide \_\_\_\_\_ mg/h IV continuous infusion (5 – 20 mg/h)
- furosemide \_\_\_\_\_ mg PO q \_\_\_\_\_ h
- bumetanide \_\_\_\_\_ mg PO q \_\_\_\_\_ h (0.5 mg; **max 10 mg in 24 hours**)
- metolazone \_\_\_\_\_ mg PO q24h, administer 30 minutes prior to loop diuretic (2.5 mg; **max 20 mg in 24 hours**)<sup>2</sup>
- \_\_\_\_\_

#### Angiotensin-Converting Enzyme-Inhibitors (ACEI)

- perindopril \_\_\_\_\_ mg PO q24h (initiation dose 2 – 4 mg; target regimen 4 – 8 mg q24h)<sup>1</sup>
- ramipril \_\_\_\_\_ mg PO q12h (initiation dose 1.25 – 2.5 mg; target regimen 5 mg q12h)<sup>1</sup>
- \_\_\_\_\_

#### Angiotensin Receptor Blockers (ARB) For Patient Intolerant to ACEI

- candesartan \_\_\_\_\_ mg PO q24h (initiation dose 4 – 8 mg; target regimen 32 mg q24h)<sup>1-3</sup>
- valsartan \_\_\_\_\_ mg PO q12h (initiation dose 40 mg; target regimen 160 mg q12h)<sup>1-3</sup>
- \_\_\_\_\_

#### Angiotensin Receptor Neprilysin Inhibitors (ARNI)

\*\*\*Patients who remain symptomatic despite triple therapy, consider changing ACEI/ARB to an ARNI\*\*\*<sup>1,9</sup>  
 \*\*\*Concomitant use with an ACEI or ARB is contraindicated;  
 if an ACEI was administered, wait 36 hours before administering ARNI\*\*\*<sup>1,9</sup>

- sacubitril 24 mg/valsartan 26 mg, 1 tab PO q12h (target regimen sacubitril 97 mg/valsartan 103 mg, 1 tab q12h)
- sacubitril 49 mg/valsartan 51 mg, 1 tab PO q12h (target regimen sacubitril 97 mg/valsartan 103 mg, 1 tab q12h)
- sacubitril 97 mg/valsartan 103 mg, 1 tab PO q12h

|               |    |              |                  |                                    |
|---------------|----|--------------|------------------|------------------------------------|
| Submitted by: |    |              |                  | <input type="checkbox"/> Read Back |
|               | ID | PRINTED NAME | YYYY-MM-DD HH:MM |                                    |
| Practitioner: |    |              |                  |                                    |
|               | ID | PRINTED NAME | YYYY-MM-DD HH:MM | SIGNATURE                          |

Document allergies on approved form and ensure medication reconciliation has been reviewed as per organizational process

## CHFS Heart Failure Order Set

### Heart Failure Medications Continued...

#### Beta-Blockers

- bisoprolol \_\_\_\_\_ mg PO q24h (initiation dose 1.25 mg; target regimen 10 mg q24h)<sup>1</sup>
- carvedilol \_\_\_\_\_ mg PO q12h  
(initiation dose 3.125 mg; target regimen 25 mg q12h [if weight greater than 50 kg, target regimen 50 mg q12h])<sup>1</sup>
- \_\_\_\_\_

#### Mineralocorticoid Receptor Antagonist (MRA)

- eplerenone \_\_\_\_\_ mg PO q24h (initiation dose 25 mg; target regimen 50 mg q24h)<sup>1-3</sup>
- spironolactone \_\_\_\_\_ mg PO q24h (initiation dose 12.5 mg; target regimen 50 mg q24h)<sup>1</sup>

#### Vasodilators

\*\*\*The combination of isosorbide dinitrate and hydralazine are recommended in addition to standard treatment for black patients with HFrEF with advanced symptoms or patients unable to tolerate ACEI, ARB or ARNI therapy\*\*\*<sup>1</sup>

- hydralazine \_\_\_\_\_ mg PO q8h (initiation dose 25 mg; target regimen 75 mg q8h)
- And**  isosorbide dinitrate \_\_\_\_\_ mg PO q8h (initiation dose 20 mg; target regimen 40 mg q8h)<sup>1</sup>
- \_\_\_\_\_

#### Sinoatrial Node Modulator

\*\*\*Ivabradine can be considered in patients with HFrEF who are in sinus rhythm with a resting heart rate of greater than or equal to 77 beats per minute and have had a previous HF hospitalization within the past year despite being at the maximally tolerated dose of beta-blockers\*\*\*<sup>10</sup>

- ivabradine \_\_\_\_\_ mg PO q12h  
(initiation dose 2.5 – 5 mg<sup>1</sup> [if greater than 75 years old, initial dose 2.5 mg]; target regimen 7.5 mg q12h<sup>1</sup>)

#### Digoxin

\*\*\*Digoxin may be considered in patients in sinus rhythm who continue to be symptomatic with triple therapy\*\*\*<sup>1,3</sup>

- digoxin \_\_\_\_\_ mg PO q24h (0.125 – 0.25 mg)

#### Sodium-glucose Cotransporter 2 (SGLT2) Inhibitor

\*\*\*SGLT2 inhibitors should be started once medically stable or upon discharge given risks of euglycemic DKA; not indicated for routine therapy in acute heart failure\*\*\*

\*\*\*Dapagliflozin may be considered in patients with mild to moderate HFrEF (LVEF less than/equal to 40%) regardless of concomitant type 2 diabetes<sup>11</sup> (do not use in patients with type 1 diabetes)\*\*\*

\*\*\*Caution should be exercised when combining SGLT2 inhibitors, ARNI, and diuretics because of their concomitant effects to promote diuresis\*\*\*<sup>11</sup>

**Note:** If serum creatinine is increasing, dapagliflozin should not be initiated or be reassessed if initiated.

- dapagliflozin 10 mg PO q24h<sup>12</sup>
- Initiate on \_\_\_\_\_ (yyyy-mm-dd) at \_\_\_\_\_ (hh:mm)

### Electrolyte Management

- Non-Critical Care Potassium Oral Replacement Clinical Protocol
- \_\_\_\_\_

|               |    |              |                  |                                    |
|---------------|----|--------------|------------------|------------------------------------|
| Submitted by: |    |              |                  | <input type="checkbox"/> Read Back |
|               | ID | PRINTED NAME | YYYY-MM-DD HH:MM |                                    |
| Practitioner: |    |              |                  |                                    |
|               | ID | PRINTED NAME | YYYY-MM-DD HH:MM | SIGNATURE                          |

Document allergies on approved form and ensure medication reconciliation has been reviewed as per organizational process

## CHFS Heart Failure Order Set

### Glycemic Management

If applicable, prescriber to complete diabetes management order set

- Diabetes Insulin Management Order Set (NPO Patient)
- Diabetes Insulin Management Order Set (Patient Eating Meals)
- Hypoglycemia Management Clinical Protocol

 \_\_\_\_\_

### Smoking Cessation

\*\*\*Pharmacological treatment combined with counselling is more effective than pharmacological treatment alone\*\*\*<sup>13</sup>

- Nicotine Replacement Therapy In-patient Clinical Protocol

If applicable, prescriber to complete Smoking Cessation Pharmacologic Aids In-patient Order Set.

### VTE Prophylaxis

#### VTE Pharmacological Prophylaxis Not Required

- No pharmacological prophylaxis: On therapeutic anticoagulation
- No pharmacological prophylaxis: Fully mobile and expected length of stay 24-48 hours and no additional risk factors
- No pharmacological prophylaxis: Bleeding/high risk of bleeding
- No pharmacological prophylaxis - Reason: \_\_\_\_\_

#### VTE Pharmacological Prophylaxis

- Initiate prescribed anticoagulant on \_\_\_\_\_ (yyyy-mm-dd) at \_\_\_\_\_ (hh:mm)

#### LMWH<sup>14</sup>

- dalteparin 5,000 units Subcutaneous q24h
- enoxaparin 40 mg Subcutaneous q24h

#### Unfractionated Heparin

- heparin 5,000 units Subcutaneous q \_\_\_\_\_ h (q8-12h)

#### VTE Mechanical Prophylaxis

\*\*\*If mechanical prophylaxis is used alone, reassess daily for conversion to anticoagulant prophylaxis\*\*\*

- Apply bilateral intermittent pneumatic compression devices<sup>14</sup>
- Apply bilateral, calf-length elastic compression stockings<sup>14</sup>

Submitted by:

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

Read Back

Practitioner:

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

Document allergies on approved form and ensure medication reconciliation has been reviewed as per organizational process

## CHFS Heart Failure Order Set

### Discharge Planning

\*\*\*Strategies to reduce readmission rates include early patient discharge planning and scheduling of follow-up appointments prior to discharge\*\*\*<sup>1-3</sup>

**Note:** Refer to heart failure discharge checklist.

#### Appointments to be Arranged Prior to Discharge

Arrange for the following appointment(s) for patient to be seen post-discharge within the time frame specified below:

- Cardiologist/Internist: - Dr. \_\_\_\_\_ within \_\_\_\_\_ week(s) of discharge
- PCP: \_\_\_\_\_ within \_\_\_\_\_ week(s) of discharge
- \_\_\_\_\_ within:  \_\_\_\_\_ day(s)  \_\_\_\_\_ week(s)

If patient does not have a PCP, ensure they are connected to a PCP before discharge as per policy/procedure. If no PCP is available, notify MD/NP for alternate provision of care arrangements

#### Referrals to be Arranged Prior to Discharge

If barriers (e.g. financial) to obtaining discharge medication(s) or equipment,<sup>15</sup> arrange referral to: \_\_\_\_\_

Smoking Cessation Program

Arrange for the following referral(s) for patient to be seen post-discharge within the time frame specified below:

- Cardiac Rehabilitation Program Reason: \_\_\_\_\_ within:  \_\_\_\_\_ day(s)  \_\_\_\_\_ week(s)
- Heart Function Clinic Reason: \_\_\_\_\_ within:  \_\_\_\_\_ day(s)  \_\_\_\_\_ week(s)
- Home and community care Reason: \_\_\_\_\_ within:  \_\_\_\_\_ day(s)  \_\_\_\_\_ week(s)
- Palliative care service Reason: \_\_\_\_\_ within:  \_\_\_\_\_ day(s)  \_\_\_\_\_ week(s)
- \_\_\_\_\_ Reason: \_\_\_\_\_ within:  \_\_\_\_\_ day(s)  \_\_\_\_\_ week(s)

\_\_\_\_\_

|               |    |              |                  |                                    |
|---------------|----|--------------|------------------|------------------------------------|
| Submitted by: |    |              |                  | <input type="checkbox"/> Read Back |
|               | ID | PRINTED NAME | YYYY-MM-DD HH:MM |                                    |
| Practitioner: |    |              |                  |                                    |
|               | ID | PRINTED NAME | YYYY-MM-DD HH:MM | SIGNATURE                          |

Document allergies on approved form and ensure medication reconciliation has been reviewed as per organizational process

## CHFS Heart Failure Order Set

### Discharge

- Discharge date: \_\_\_\_\_ (yyyy-mm-dd)                       Length of stay (LOS): \_\_\_\_\_ day(s)  
 Discharge patient to:     Home                       Complex Continuing Care     Long Term Care     \_\_\_\_\_  
 Discharge diagnosis: \_\_\_\_\_  
 Comorbidities: \_\_\_\_\_

### Clinical Assessment at Discharge

- New York Heart Association (NYHA) Functional Classification<sup>16</sup>:     Class I     Class II     Class III     Class IV  
 Left Ventricle Ejection Fraction (LVEF): \_\_\_\_\_ %  
 Discharge Weight: \_\_\_\_\_ kg  
**Lab Values:**     Creatinine: \_\_\_\_\_     K: \_\_\_\_\_     Na: \_\_\_\_\_     Other(s): \_\_\_\_\_

### Discharge Information

- Ensure discharge Medication Reconciliation process has been completed as per policy/procedure<sup>17</sup>  
 Ensure a follow-up phone call to patient/caregiver has been arranged to be done within \_\_\_\_\_ hours of discharge (24-72 hours)<sup>18-20</sup>

### For Patient

- Ensure a copy of the Patient Discharge and Follow-up Information page(s), the patient's care plan, and the Medication Reconciliation form have been provided to the patient/caregiver as per policy/procedure<sup>17,20-22</sup>

### For Community Health Care Providers

- Ensure a copy of this document, the patient's care plan, the Discharge Summary, the Medication Reconciliation form, Letter to the PCP and other relevant documents have been provided to the following as per policy/procedure<sup>17,20-22</sup>:  
 PCP     Home care service                       Specialist: \_\_\_\_\_  
 Patient's community pharmacy     \_\_\_\_\_

### Patient Education and Self-management

- Initiate and complete the applicable patient education checklist<sup>23</sup> with patient/caregiver and ensure discharge instructions have been provided as per policy/procedure. Use teach-back technique to assess and confirm patient/caregiver understanding<sup>24,25</sup>  
 Ensure the following education is provided at a level appropriate for the patient/caregiver<sup>16</sup>:
  - Advance care directives
  - Definition of heart failure and cause
  - Physical activity/exercises<sup>26</sup>
  - Daily weight monitoring
  - Diuretic monitoring and management
  - Self-management
  - Diet, e.g. nutrition, fluid, salt restriction
  - Lifestyle, e.g. alcohol, smoking
  - Smoking Cessation
  - Heart failure risk modification
  - Medication management
  - Symptoms of worsening heart failure
  - When to seek medical attention, e.g. specific symptoms or weight changes Advise patient to talk to their PCP about recommended vaccinations  
 Provide applicable written education materials<sup>27</sup> in patient's preferred language and review with patient/caregiver as per policy/procedure<sup>21,28</sup>  
 \_\_\_\_\_

|               |    |              |                  |                                    |
|---------------|----|--------------|------------------|------------------------------------|
| Submitted by: |    |              |                  | <input type="checkbox"/> Read Back |
|               | ID | PRINTED NAME | YYYY-MM-DD HH:MM |                                    |
| Practitioner: |    |              |                  |                                    |
|               | ID | PRINTED NAME | YYYY-MM-DD HH:MM | SIGNATURE                          |

## CHFS Heart Failure Discharge Patient Information

This 'Heart Failure Discharge and Patient Information' section is to provide instructions to the patient, and when completed, should be printed and given directly to the patient for their review and to take with them upon discharge.

### Instructions

- Review the information provided to you before you go home and again when you arrive home.
- Bring your Medication Reconciliation form and plan of care to your Pharmacist at your next visit.
- Bring this document, the Medication Reconciliation form and plan of care to your Primary Care Provider, e.g. family doctor or nurse practitioner.

### Information

- The Canadian Heart Failure Society Patient Resources: <https://heartfailure.ca/education/patient-resources>
- The Canadian Cardiovascular Society Heart Failure Program: <http://www.ccs.ca/en/guidelines/heart-failure-program>
- Heart and Stroke Foundation:  
[https://www.heartandstroke.ca/-/media/pdf-files/canada/health-information-catalogue/en-living-with-heart-failure\\_ashx?rev=3238e9abfab4027b4b56a042a5d804e&hash=1B4D04630249286D09B8544119E36772](https://www.heartandstroke.ca/-/media/pdf-files/canada/health-information-catalogue/en-living-with-heart-failure_ashx?rev=3238e9abfab4027b4b56a042a5d804e&hash=1B4D04630249286D09B8544119E36772)
- How to stop smoking: Smokers Helpline: 1-877-513-5333 <http://www.smokershelpline.ca>
- Finding a family doctor or nurse practitioner: Health Care Connect: 1-800-445-1822  
<https://www.ontario.ca/page/find-family-doctor-or-nurse-practitioner>

### Home Care Services

- If home care services arrangements have been started for you, and you have not been contacted by your home care coordinator within \_\_\_\_\_ hours, please phone the following number: \_\_\_\_\_
- If respiratory services arrangements have been made for you, and you have questions or concerns, please phone the following number: \_\_\_\_\_

### Diagnostic Tests

**\*\*\*Patient with HF seen in the ED and/or admitted to hospital for HF should have an assessment of LV function within last 12 months of admission date or planned within 30 days from discharge from ED\*\*\*<sup>8</sup>**

- |  |   |
|--|---|
| <input type="checkbox"/> Echocardiogram Reason: _____                              | Phone Number: _____   |
| <input type="checkbox"/> Arranged by hospital: Date: _____ Time: _____             | <b>or</b> <input type="checkbox"/> Patient will be notified |
| <input type="checkbox"/> Patient to arrange test. Test to be done in _____ week(s) | <b>or</b> _____ month(s)                                    |
| <input type="checkbox"/> Cardiac MRI Reason: _____                                 | Phone Number: _____   |
| <input type="checkbox"/> Arranged by hospital: Date: _____ Time: _____             | <b>or</b> <input type="checkbox"/> Patient will be notified |
| <input type="checkbox"/> Patient to arrange test. Test to be done in _____ week(s) | <b>or</b> _____ month(s)                                    |
| <input type="checkbox"/> _____   | Phone Number: _____   |
| <input type="checkbox"/> Arranged by hospital: Date: _____ Time: _____             | <b>or</b> <input type="checkbox"/> Patient will be notified |
| <input type="checkbox"/> Patient to arrange test. Test to be done in _____ week(s) | <b>or</b> _____ month(s)                                    |



## CHFS Heart Failure Discharge Patient Information

### Appointments

|  |   |
|--|---|
| <input checked="" type="checkbox"/> Heart Failure Clinic: _____                    | Phone Number: _____   |
| <input type="checkbox"/> Arranged by hospital: Date: _____ Time: _____             | <b>or</b> <input type="checkbox"/> Patient will be notified |
| <input type="checkbox"/> Patient to arrange appointment to be seen in _____ day(s) | <b>or</b> _____ week(s)                                     |
| <input checked="" type="checkbox"/> Primary Care Provider: _____                   | Phone Number: _____   |
| <input type="checkbox"/> Arranged by hospital: Date: _____ Time: _____             | <b>or</b> <input type="checkbox"/> Patient will be notified |
| <input type="checkbox"/> Patient to arrange appointment to be seen in _____ day(s) | <b>or</b> _____ week(s)                                     |
| <input checked="" type="checkbox"/> Cardiologist/Internist - Dr. _____             | Phone Number: _____   |
| <input type="checkbox"/> Arranged by hospital: Date: _____ Time: _____             | <b>or</b> <input type="checkbox"/> Patient will be notified |
| <input type="checkbox"/> Patient to arrange appointment to be seen in _____ day(s) | <b>or</b> _____ week(s)                                     |
| <input checked="" type="checkbox"/> Cardiac Rehabilitation Program: _____          | Phone Number: _____   |
| <input type="checkbox"/> Arranged by hospital: Date: _____ Time: _____             | <b>or</b> <input type="checkbox"/> Patient will be notified |
| <input type="checkbox"/> Patient to arrange appointment to be seen in _____ day(s) | <b>or</b> _____ week(s)                                     |
| <input type="checkbox"/> Diabetes Clinic: _____                                    | Phone Number: _____   |
| <input type="checkbox"/> Arranged by hospital: Date: _____ Time: _____             | <b>or</b> <input type="checkbox"/> Patient will be notified |
| <input type="checkbox"/> Patient to arrange appointment to be seen in _____ day(s) | <b>or</b> _____ week(s)                                     |
| <input type="checkbox"/> Smoking Cessation Program: _____                          | Phone Number: _____   |
| <input type="checkbox"/> Arranged by hospital: Date: _____ Time: _____             | <b>or</b> <input type="checkbox"/> Patient will be notified |
| <input type="checkbox"/> Patient to arrange appointment                            |   |
| <input type="checkbox"/> _____   | Phone Number: _____   |
| <input type="checkbox"/> Arranged by hospital: Date: _____ Time: _____             | <b>or</b> <input type="checkbox"/> Patient will be notified |
| <input type="checkbox"/> Patient to arrange appointment to be seen in _____ day(s) | <b>or</b> _____ week(s)                                     |

## CHFS Heart Failure Order Set

### Order Set Development and Implementation Consideration

The CHFS acknowledges the partnership with Think Research and the important contribution of the following hospitals' heart failure order sets in the development of the present document: Alberta Health Services, the St-Boniface Hospital (Winnipeg), and the Sunnybrook Health Sciences Centre (Toronto).

### Updated

This order set was last updated in May 2020.

### Abbreviations

|  |  |
|--|--|
| ACEI = Angiotensin-Converting Enzyme Inhibitor | GFR = Glomerular Filtration Rate                     |
| ARB = Angiotensin II Receptor Blocker          | HF = Heart Failure                                   |
| BioMed = Biomedical Engineering                | HFrEF = Heart Failure with Reduced Ejection Fraction |
| BNP = Brain Natriuretic Peptide                | LV = Left Ventricle                                  |
| CAM = Confusion Assessment Method              | LVEF = Left Ventricle Ejection Fraction              |
| DKA = Diabetic Ketoacidosis                    | NT-proBNP = Prohormone of BNP                        |
| ED = Emergency Department                      | PAP = Positive Airway Pressure                       |
| EF = Ejection Fraction                         | PCP = Primary Care Provider                          |

### Patient Care Considerations

- **Antiplatelet Therapy:** Antiplatelet therapy (e.g. acetylsalicylic acid) is recommended in patients with HF who have had or at risk for atherosclerotic cardiovascular events.<sup>1</sup>
- **BNP and NT-proBNP:** BNP and NT-proBNP are natriuretic peptide (NP) biomarkers that are used to establish the presence and severity of HF.<sup>9</sup> NP screening can be helpful in establishing if a patient is at risk for HF and if echocardiography is necessary. The following table provides information regarding the NP levels and diagnosis of HF<sup>1</sup>:

|           | Age             | HF is unlikely      | HF is possible but alternative diagnoses to be considered | HF is very likely       |
|-----------|-----------------|---------------------|---|-------------------------|
| BNP       | All             | Less than 100 pg/mL | 100 – 150 pg/mL   | Greater than 500 pg/mL  |
| NT-proBNP | Less than 50    | Less than 300 pg/mL | 300 – 450 pg/mL   | Greater than 450 pg/mL  |
|           | 50 – 75         |                     | 450 – 900 pg/mL   | Greater than 900 pg/mL  |
|           | Greater than 75 |                     | 900 – 1800 pg/mL  | Greater than 1800 pg/mL |

**Note:** BNP levels may increase early after initiation of ARNI therapy as BNP is a substrate for neprilysin.<sup>9,29</sup> Prognostic value of BNP typically resumes after the first 6 months of therapy. Though NT-proBNP is not a substrate of neprilysin, its level may lower early after initiation of ARNI therapy; however, it retains its prognostic value during this time.<sup>29,30</sup>

- **Choosing an ACEI in HF:** Determining which ACEI to prescribe in patients with HF depends on several factors, including: ejection fraction (EF), stroke volume (SV), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), renal function, adverse effects, and mortality. Many factors go into determining which ACEI to choose for patients with HF and more research needs to be done to determine if there is an ACEI that is superior to others, particularly in reducing rehospitalization and cardiac death.<sup>31</sup>
- **Discharge Checklist:** Key considerations for discharging a patient include the following<sup>1</sup>:
  - **Symptoms and Disease:**
    - Intercurrent cardiac illness adequately diagnosed and treated
    - Presenting symptoms resolved
    - Chronic oral HF therapy initiated, titrated, and optimized (or plan for same)

## CHFS Heart Failure Order Set

- **Stability:**
  - Return to "dry" weight and stable for greater than 24 hours
  - Vital signs resolved and stable for greater than 24 hours, especially blood pressure and heart rate
  - Greater than 30% decrease in natriuretic peptide level from time of admission and relatively free from congestion
- **Transition:**
  - Communication to primary care provider and/or specialist physician and/or multidisciplinary disease management program (ideally patient to be seen by cardiologist or internist within 7 days of leaving the hospital)
  - Clear discharge plan for laboratory tests, follow-up, and other testing
  - Education initiated, understood by patient, and continued education planned; this includes:
    - Formal education session on HF management for patient and family members
    - Education on controlling sodium intake, weighing self, and recognizing symptoms of worsening HF
    - Education on algorithms to adjust diuretics in patients with recurrent fluid retention
- **MRAs and Potassium and Kidney Function:** MRAs can increase serum potassium, especially when a patient has a dehydrating illness where renal dysfunction can worsen. This requires patients to have kidney function (e.g. creatinine, GFR) and potassium, to be closely monitored when on these medications.<sup>1</sup>
- **Patients at Risk for Hypercapnia<sup>4</sup>:** Chronic Obstructive Pulmonary Disease (COPD) is the most common disease to cause hypercapnia<sup>4</sup>; other patients at risk for hypercapnic respiratory failure include those with cystic fibrosis (CF), non-CF bronchiectasis (often in association with COPD or severe asthma), severe kyphoscoliosis or severe ankylosing spondylitis, severe lung scarring from old tuberculosis (especially with thoracoplasty), morbid obesity (BMI > 40 kg/m<sup>2</sup>), musculoskeletal disorders with respiratory muscle weakness (on home mechanical ventilation), overdose of opioids, benzodiazepines or other respiratory depressant drugs. The target SpO<sub>2</sub> in patients with COPD who are at risk of hypercapnia is 88-92%. The target SpO<sub>2</sub> in patients with other risk factors for hypercapnia is 88-92%; this is based on expert opinion which was extrapolated from observational studies.
- **SGLT2 Inhibitor:** The Canadian Cardiovascular Society (CCS) recommend SGLT2 inhibitors, such as dapagliflozin, be used in patients with mild to moderate HF due to reduced LVEF (less than/equal to 40%) and without concomitant diabetes, to improve symptoms and quality of life and to reduce the risk of hospitalization and cardiovascular mortality (Conditional Recommendation, High-Quality Evidence).<sup>11</sup> This recommendation is based of the results of the Dapagliflozin on Incidence of Worsening Heart Failure or Cardiovascular Death in Patients with CHF (DAPA-HF) trial.<sup>12</sup>
- **Sleep Apnea:** Obstructive sleep apnea (OSA) and central sleep apnea (CSA) are the main types of sleep disordered breathing (SDB). Around 40% of patients with HF have CSA and 11% have OSA. Many patients with HF with SDB go undiagnosed, likely due to limited resources and awareness. It is recommended that clinicians treating patients with HF refer to experienced sleep physicians and sleep laboratories to help differentiate between OSA and CSA.<sup>1</sup>
- **Supplemental O<sub>2</sub> and Target Ranges:** In acutely ill adults, evidence shows that liberal O<sub>2</sub> therapy increases mortality without improving other patient-important outcomes. Supplemental O<sub>2</sub> might become unfavourable above an SpO<sub>2</sub> range of 94-96%.<sup>32</sup> A systematic review and meta-analysis by Chu et al shows that patients treated liberally with O<sub>2</sub> had a dose-dependent increased risk of short-term and long-term mortality.<sup>32</sup> Individual randomised controlled trials have suggested an increased risk of respiratory failure, new shock episodes, recurrent myocardial infarction, arrhythmia, and other cardiovascular adverse events as potential mechanisms of harm with liberal O<sub>2</sub> therapy.<sup>32</sup> An upper level of 96% avoids the potential risks of hyperoxia and allows for patient improvement to be recognized earlier during monitoring so that O<sub>2</sub> can be down-titrated.<sup>6</sup>

## CHFS Heart Failure Order Set

### Administration/Organizational Considerations

- **Advance Care Planning Discussions:** Advance Care Planning discussions may be undertaken by different health care professionals, e.g. MD/NP, nurse, SW. Localization of this content will involve alignment with the facility's resources, workflows, and policy/procedure. Advance Care Planning discussions may trigger a process leading to the creation of a separate legal Advance Directive document.<sup>33</sup> If the patient has an Advance Directive, it should be incorporated into the patient's Advance Care Plan in alignment with the facility's policy/procedure, and applicable law.
- **Code Status:** Facilities should localize code status orders in alignment with policy/procedure and applicable law.
- **Malnutrition Screen:** Facilities should have a process in place to screen all patients for malnutrition with a simple assessment tool such as the Canadian Nutrition Screening Tool.
- **Risk Scores:** HF prognostic and risk scores can be easily accessed and calculated, and when possible should be incorporated into practice.<sup>1</sup> Organizations are to determine what risk scores are appropriate in their setting and implement them into practice as they see fit.

### References

Key references<sup>1-33</sup>

All medication guidance has been reviewed using Lexicomp and Compendium of Pharmaceuticals and Specialties (eCPS).

1. Ezekowitz JA, O'Meara E, McDonald MA, et al. 2017 Comprehensive update of the Canadian Cardiovascular Society guidelines for the management of heart failure. *Can J Cardiol.* 2017;33(11):1342-1433. doi:10.1016/j.cjca.2017.08.022
2. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol.* 2013;62(16):e147-239. doi:10.1016/j.jacc.2013.05.019
3. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J.* 2016;37(27):2129-2200. doi:10.1093/eurheartj/ehw128
4. O'Driscoll BR, Howard LS, Earis J, et al. BTS guideline for oxygen use in adults in healthcare and emergency settings. *Thorax.* 2017;72(Suppl 1):i1-i90.
5. Siemieniuk RAC, Chu DK, Kim LH-Y, et al. Oxygen therapy for acutely ill medical patients: a clinical practice guideline. *BMJ.* October 2018;k4169. doi:10.1136/bmj.k4169
6. Beasley R, Chien J, Douglas J, et al. Thoracic Society of Australia and New Zealand oxygen guidelines for acute oxygen use in adults: 'swimming between the flags.' *Respirology.* 2015;20(8):1182-1191. doi:10.1111/resp.12620
7. American Sleep Apnea Association. CPAP use in a hospital or surgical setting. 2007. [www.sleepapnea.org](http://www.sleepapnea.org).
8. The Canadian Cardiovascular Society. The Canadian Cardiovascular Society quality indicators e-catalogue for heart failure - a CCS consensus document. 2019.
9. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure. *Circulation.* 2017;136(6). doi:10.1161/CIR.0000000000000509
10. Perras C, de Léséleuc L, Ahuja T, Loshak H. Ivabradine for heart failure. *CADTH Technol Rev Optim Use 360 Resport.* 2019;(23):12.

## CHFS Heart Failure Order Set

11. O'Meara E, McDonald M, Chan M, et al. CCS/CHFS Heart failure guidelines: clinical trial update on functional mitral regurgitation, SGLT2 inhibitors, ARNI in HFpEF, and tafamidis in amyloidosis. *Can J Cardiol.* 2020;36(2):159-169. doi:10.1016/j.cjca.2019.11.036
12. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. *N Engl J Med.* 2019;381(21):1995-2008. doi:10.1056/NEJMoa1911303
13. Stead LF, Lancaster T. Behavioural interventions as adjuncts to pharmacotherapy for smoking cessation. *Cochrane Database Syst Rev.* 2012;(12). doi:10.1002/14651858.CD009670.pub2
14. Thrombosis Canada. Thromboprophylaxis: hospitalized medical patients. 2019. <https://thrombosiscanada.ca/wp-content/uploads/2019/05/Thromboprophylaxis-Medical-Patients-2019Apr30.pdf>.
15. Canadian Medical Association. CMA position statement: ensuring equitable access to care: strategies for governments, health system planners, and the medical profession. 2013:1-17.
16. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J.* 2016;37(27):2129-2200m. doi:10.1093/eurheartj/ehw128
17. Canadian Patient Safety Institute/ISMP Canada. Medication reconciliation in acute care. Getting started kit. 2017:1-69.
18. Healthcare Insurance Reciprocal of Canada. HIROC. Post discharge phone calls. *HIROC.* 2013:1-2.
19. Agency for Healthcare and Research Quality. Re-engineered discharge (RED) toolkit. Tool 5: how to conduct a post-discharge phone call. *AHRQ.* 2013.
20. Auerbach AD, Kripalani S, Vasilevskis EE, et al. Preventability and causes of readmissions in a national cohort of general medicine patients. *JAMA Intern Med.* 2016;176(4):484-493.
21. Health Quality Ontario. Health Quality Ontario home and community care hospital readmission. 2015.
22. Agency for Healthcare Research and Quality. Re-engineered discharge (RED) toolkit. Tool 1: overview. *AHRQ.* 2013.
23. Agency for Healthcare Research and Quality. IDEAL discharge planning overview, process, and checklist. *AHRQ.* 2013:1-7.
24. Agency for Healthcare Research and Quality. Use the teach-back method: tool 5. *AHRQ.* 2015:18-20.
25. National Center for Ethics in Healthcare. "Teach Back". A tool for improving provider-patient communication. *Natl Cent Ethics Healthc.* 2006;(April):1-2.
26. Ezekowitz JA, O'Meara E, McDonald MA, et al. 2017 Comprehensive update of the Canadian Cardiovascular Society guidelines for the management of heart failure. *Can J Cardiol.* 2017;33(11):1342-1433. doi:10.1016/j.cjca.2017.08.022
27. McCarthy DM, Engel KG, Buckley BA, et al. Emergency department discharge instructions: lessons learned through developing new patient education materials. *Emerg Med Int.* 2012;2012:1-7. doi:10.1155/2012/306859
28. Agency for Healthcare Research and Quality. Re-engineered discharge (RED) toolkit. Tool 6: how to monitor RED implementation and outcomes. *AHRQ.* <https://www.ahrq.gov/professionals>. Published 2013.
29. Myhre PL, Vaduganathan M, Claggett B, et al. B-type natriuretic peptide during treatment with sacubitril/valsartan. *J Am Coll Cardiol.* 2019;73(11):1264-1272. doi:10.1016/j.jacc.2019.01.018
30. Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. *N Engl J Med.* 2019;380(6):539-548. doi:10.1056/NEJMoa1812851

## CHFS Heart Failure Order Set

31. Sun W, Zhang H, Guo J, et al. Comparison of the efficacy and safety of different ACE inhibitors in patients with chronic heart failure. *Medicine (Baltimore)*. 2016;95(6). doi:10.1097/MD.0000000000002554
32. Chu DK, Kim LH-Y, Young PJ, et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. *The Lancet*. 2018;391(10131):1693-1705. doi:10.1016/S0140-6736(18)30479-3
33. Canadian Hospice Palliative Care Association. Advance care planning in Canada: national framework. 2012:1-42. <http://www.advancecareplanning.ca/wp-content/uploads/2016/08/ACP-Framework-2012-ENG.pdf>.